GlassScriptPhysician profile
Subroto Kundu
NPI 1063426302
$17,433.44
in general payments reported to CMS, 2019-2025
46 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,682 · 2020: $1,804 · 2021: $2,898 · 2022: $2,752 · 2023: $983 · 2024: $1,161 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,650.91 | 2019-2024 | |
| Ucb, INC. | $1,804.45 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Genzyme Corporation | $854.88 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $756.71 | 2019-2022 | |
| Sk Life Science, INC. | $622.88 | 2020-2025 | Xcopri |
| Eisai INC. | $611.20 | 2019-2023 | |
| Lilly USA, LLC | $610.30 | 2019-2024 | Kisunla, Emgality, Reyvow |
| Celgene Corporation | $602.96 | 2021-2025 | Zeposia |
| Abbvie INC. | $550.59 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $451.48 | 2020-2022 | |
| Emd Serono, INC. | $438.08 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $426.69 | 2019-2024 | Austedo Xr |
| Argenx US, INC. | $425.65 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $393.81 | 2022-2025 | |
| Biogen, INC. | $390.76 | 2019-2023 | Vumerity |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subroto Kundu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.